TVTX FY 2025 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$491M+110.5% YoY

Gross Profit

$420M85.5% margin

Operating Income

-$63M-12.8% margin

Net Income

-$50M-10.2% margin

EPS (Diluted)

$-0.56

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$38M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$605M

Total Liabilities

$490M

Stockholders' Equity

$115M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$491M	$233M	+110.5%
Gross Profit	$420M	$225M	+86.2%
Operating Income	-$63M	-$324M	+80.6%
Net Income	-$50M	-$322M	+84.4%